Loading
A phase 2 trial of Sonrotoclax in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by BeiGene, active and no longer recruiting.
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT05479994 by BeiGene, with 100 participants enrolled, started 2022-10-25 and due to reach its primary completion in 2025-01-24. Interventions recorded: BGB-11417.
Shares Sonrotoclax, BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.